ArticleBritish journal of cancer2021
Radiomics predicts risk of cachexia in advanced NSCLC patients treated with immune checkpoint inhibitors.
Article in British journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Cancer cachexia reduces the efficacy of immune checkpoint inhibitors in cancer patients.Aging · 2024Pooled it
- Immediate post-microwave ablation computed tomography model may better predict short-term response of stage I non-small cell lung cancer.World journal of radiology · 2026Article
- Pre-therapeutic prediction of cachexia in lymphoma patients using [European journal of clinical nutrition · 2026Article
- Function ofEJNMMI reports · 2025Article
- Progress and challenges of artificial intelligence in lung cancer clinical translation.NPJ precision oncology · 2025Review
- Imaging Cancer-associated Cachexia: Utilizing Clinical Imaging Modalities for Early Diagnosis.Radiology. Imaging cancer · 2025Review
- Habitat radiomics analysis for progression free survival and immune-related adverse reaction prediction in non-small cell lung cancer treated by immunotherapy.Journal of translational medicine · 2025Article
- Weight censorial score: estimation of the weight loss during concurrent chemo-radiotherapy in nasopharyngeal carcinoma patients by image features predicts prognosis.La Radiologia medica · 2025Article
- Pan-cancer secreted proteome and skeletal muscle regulation: insight from a proteogenomic data-driven knowledge base.Functional & integrative genomics · 2025Review
- Construction and validation of deep learning model for cachexia in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors: a multicenter study.Translational lung cancer research · 2024Article
- Artificial intelligence in immunotherapy PET/SPECT imaging.European radiology · 2024Review
- [Advancements in Radiomics for Immunotherapy of Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours.Nature reviews. Cancer · 2024Review
- Prognostic models for immunotherapy in non-small cell lung cancer: A comprehensive review.Heliyon · 2024Review
- Combined clinical variable and radiomics of post-treatment total body scan for prediction of successful I-131 ablation in low-risk papillary thyroid carcinoma patients.Scientific reports · 2024Article
- Integrating Artificial Intelligence and PET Imaging for Drug Discovery: A Paradigm Shift in Immunotherapy.Pharmaceuticals (Basel, Switzerland) · 2024Review
- PET Radiomics and Response to Immunotherapy in Lung Cancer: A Systematic Review of the Literature.Cancers · 2023Review
- Editorial: Immunology of cachexia.Frontiers in immunology · 2023Article
- What does radiomics do in PD-L1 blockade therapy of NSCLC patients?Thoracic cancer · 2022Review
- Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy.Journal for immunotherapy of cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundApproximately 50% of cancer patients eventually develop a syndrome of prolonged weight loss (cachexia), which may contribute to primary resistance to immune checkpoint inhibitors (ICI). This study utilised radiomics analysis of
methodsBaseline (pre-therapy) PET/CT images and clinical data were retrospectively curated from 210 ICI-treated NSCLC patients from two institutions. A radiomics signature was developed to predict the cachexia with PET/CT images, which was further used to predict durable clinical benefit (DCB), progression-free survival (PFS) and overall survival (OS) following ICI.
resultsThe radiomics signature predicted risk of cachexia with areas under receiver operating characteristics curves (AUCs) ≥ 0.74 in the training, test, and external test cohorts. Further, the radiomics signature could identify patients with DCB from ICI with AUCs≥0.66 in these three cohorts. PFS and OS were significantly shorter among patients with higher radiomics-based cachexia probability in all three cohorts, especially among those potentially immunotherapy sensitive patients with PD-L1-positive status (p < 0.05).
conclusionsPET/CT radiomics analysis has the potential to predict the probability of developing cachexia before the start of ICI, triggering aggressive monitoring to improve potential to achieve more clinical benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.